New drug shows promise in early trial for advanced cancers
NCT ID NCT02437227
First seen May 18, 2026 · Last updated May 20, 2026 · Updated 1 time
Summary
This early-stage study tested a new drug, CCT3833, in 31 adults with advanced solid tumors, including melanoma. The main goal was to find a safe dose and understand side effects. Researchers also looked at how the drug moves through the body. This is not a cure, but a step toward better controlling advanced cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Christie NHS Foundation Trust
Manchester, Greater Manchester, M20 4BX, United Kingdom
-
Royal Marsden NHS Foundation Trust
Sutton, Surrey, SM2 5PT, United Kingdom
Conditions
Explore the condition pages connected to this study.